论文部分内容阅读
早期原发性肝癌的诊断虽然通过甲胎蛋白的检测,其阳性率已有明显提高,但仍有30%左右的阴性结果。5’-核苷酸磷酸二酯酶同功酶-V(简称5’-NPDase-V)用于检测AFP阴性肝癌患者,与AFP协同诊断肝癌,可以起到相互补充的作用。1973年美国Tsou首先报导应用5’-核苷酸磷酸二酯酶同功酶-V诊断早期肝癌,第十二届国际肿瘤会议并将该同功酶的检测列入肝癌诊断的新方法,因此受到国际上的重视。现将该同功酶的研究概况及临床应用作一知识性的介绍。
Although the diagnosis of early primary liver cancer was confirmed by the detection of alpha-fetoprotein, the positive rate has been significantly improved, but there are still about 30% of negative results. 5’-nucleotide phosphodiesterase isoenzyme-V (abbreviated as 5’-NPDase-V) is used to detect patients with AFP-negative liver cancer. Synergistic diagnosis of liver cancer with AFP can complement each other. In 1973, Tsou of the United States first reported the use of 5’-nucleotide phosphodiesterase isoenzyme-V in the diagnosis of early stage liver cancer. The 12th International Conference on Tumors and the detection of this isozyme were included in the new method of diagnosis of liver cancer. It has received international attention. Now we will make an introduction to the research and clinical application of this isozyme.